TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Core Viewpoint - TransCode Therapeutics, Inc. has announced a 1-for-33 reverse stock split effective December 4, 2024, to increase its stock price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert thirty-three current shares into one new share, reducing the number of outstanding shares from 17,265,658 to approximately 696,233 [2]. - No fractional shares will be issued; instead, stockholders will have fractional shares rounded up to the nearest whole number [2]. - The reverse stock split will also adjust the exercise prices of outstanding stock options and warrants, as well as the number of shares under stock incentive plans [2]. Group 2: Company Information - TransCode is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics, utilizing its proprietary TTX nanoparticle platform [5]. - The lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [5]. - The company is developing a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for cancer treatment [5]. Group 3: Administrative Details - Vstock Transfer LLC will serve as the exchange agent for the reverse stock split, and stockholders will not need to take action to receive post-split shares [3]. - The CUSIP number for the company will change to 89357L402 as of the effective time of the reverse stock split [4].